Xenon Pharmaceuticals Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications.
Current Price
$54.68
+1.17%Profile
Valuation (TTM)
Market Cap$4.55B
P/E-11.87
EV—
P/B7.82
Shares Out83.19M
P/Sales—
Revenue$0.00
EV/EBITDA—
Xenon Pharmaceuticals Inc (XENE) Stock Analysis
Market Cap$4.55B
Current Price$54.68
P/E Ratio-11.87
Forward P/E—
PEG Ratio-0.29
EPS$-4.36
Book Value$6.99
P/B Ratio7.82
XENE Financial Charts
FCF vs CAPEX
FCFCAPEX
Cash vs Debt
Net Cash: 191M
Revenue
7M
FY19
32M
FY20
18M
FY21
9M
FY22
—
FY23
—
FY24
8M
FY25
Net Income
—
FY19
—
FY20
—
FY21
—
FY22
—
FY23
—
FY24
—
FY25
XENE 52-Week Range
$28.49
$62.76
50-Day MA: $56.30200-Day MA: $44.86
Did you know?
XENE's revenue grew at a 1.6% CAGR over the last 6 years.
Xenon Pharmaceuticals Inc (XENE) Financial Summary
Xenon Pharmaceuticals Inc (XENE) is a Healthcare company in the Biotechnology industry, listed on NASDAQ. The stock currently trades at $54.68 with a market capitalization of $4.55B.
Key valuation metrics include a P/E ratio of -11.87, price-to-book ratio of 7.82, and EPS of $-4.36. and return on equity of -65.9%.
XENE Key Financial Metrics
| Metric | Value |
|---|---|
| Market Cap | $4.55B |
| P/E Ratio | -11.87 |
| EPS | $-4.36 |
| P/B Ratio | 7.82 |
| Return on Equity | -65.9% |
| Debt/Equity | 0.01 |
XENE Revenue & Earnings History
| Year | Revenue | Net Income |
|---|---|---|
| FY19 | $6.83M | $-41.59M |
| FY20 | $32.17M | $-28.84M |
| FY21 | $18.44M | $-78.88M |
| FY22 | $9.43M | $-125.37M |
| FY23 | $0.00 | $-182.39M |
| FY24 | $0.00 | $-234.33M |
| FY25 | $7.50M | $-345.91M |
XENE Quality Indicators
Xenon Pharmaceuticals Inc and an operating margin of -4974.3%. Return on equity stands at -65.9%. The current ratio is 13.42. Debt-to-equity ratio is 0.01.
About Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications.
XENE Free Cash Flow
Xenon Pharmaceuticals Inc generated $-279.92M in trailing twelve-month free cash flow, representing an FCF yield of -6.15%. This low FCF yield may reflect heavy reinvestment or growth spending.
XENE Shares Outstanding
Xenon Pharmaceuticals Inc has 0.08 billion shares outstanding at a share price of $54.68, giving it a market capitalization of $4.55B.